Voyageur Pharmaceuticals (TSE:VM)
:VM
Want to see TSE:VM full AI Analyst Report?
VM Stock Chart & Stats
C$0.17
>-C$0.01(-5.56%)
At close: 4:00 PM EST
C$0.17
>-C$0.01(-5.56%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.36
Previous CloseN/A
Volume12.11K
Average Volume (3M)72.03K
Market Cap
C$17.95M
Enterprise ValueC$15.22M
Total Cash (Recent Filing)C$75.71K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta-0.53
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding179,475,860
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet RiskLow debt levels materially reduce short-term solvency risk and give management flexibility to execute development and commercialization plans without immediate refinancing pressure. Over 2–6 months, light leverage supports runway extensions and strategic optionality while losses persist.
Rapid Revenue GrowthSustained high revenue growth indicates tangible progress toward commercial adoption of product-derived offerings. If growth reflects genuine customer traction in target markets (medical and specialty uses), it provides a foundation to scale fixed-cost absorption and improve long-term unit economics.
Niche, Mineral-Derived Product FocusA clear product niche (mineral-sourced barium sulfate for radiology contrast and specialty industrial uses) gives a differentiated addressable market and regulatory/product qualification pathways. This vertical focus can create durable barriers to entry via technical know-how and qualification timelines.
Bears Say
Negative Margins And Large Operating LossesPersistently negative gross margins and large operating losses signal the business is not yet generating unit economics that cover costs. Over several months this pressures the path to sustainable profitability and implies continued investment or structural margin improvement is required to reach break-even.
Weak Cash Generation / Free Cash FlowMeaningful negative operating and free cash flows indicate the company is burning cash at operational levels rather than generating it, increasing reliance on external financing. This structural cash burn constrains ability to fund ongoing development without dilutive or debt financing over the medium term.
Equity Erosion / Balance Sheet PressureDeclining equity and negative ROE reflect that losses are eroding shareholders' capital, reducing financial resilience. Even with low leverage, persistent equity deterioration narrows strategic options and may necessitate capital raises that affect governance or ownership structure over a multi-month horizon.
Voyageur Pharmaceuticals News
VM FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.36 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$17.95M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 53 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 179,475,860 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.
Technical Analysis
Options Prices
Currently, No data available
---